Announcing a new article publication in BIO Integration. The authors of this article developed CellDeathAnalysis (v0.4.0), an ...
(Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year landmark Phase 1b data from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), an Fc-enhanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results